Merck & Co., Inc. Q1 2026 Earnings Recap

Merck reported year-over-year growth, highlighting progress in oncology, new product launches, and pipeline advancements. The stock finished up 1.1% after earnings, signaling a steady market reaction as investors digested continued pipeline development and a stable outlook.

Key Takeaways

• Revenue reached $16.3 billion for the quarter, supported by strength in oncology, animal health, and new product contributions.
• Product pipeline saw notable milestones, including FDA approval of IDVYNSO for HIV-1 and priority review for I-DXd in small cell lung cancer.
• The company launched NUMELVI in animal health and announced the pending acquisition of Terns Pharmaceuticals (TERN-701 for chronic myeloid leukemia).
• Merck is in the process of launching over 20 new products, with management emphasizing a reorganized commercial business unit structure to execute the strategy.
• Management reiterated confidence in the outlook for 2026 and highlighted investments in AI partnerships to advance R&D.